Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 12:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2929–2952 of 185,080 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: NOT program Clear all

Conditions: Hailey Hailey Disease
Interventions: Guselkumab; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Metastatic Breast Cancer
Interventions: Lapatinib and RAD-001; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Renal Dialysis
Interventions: BAY1213790, 0.9% sodium chloride solution; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 4
States / cities: Chula Vista, California • Bradenton, Florida • Chicago, Illinois + 1 more

Conditions: Diabetes Mellitus, Type 1
Interventions: AT247, NovoLog, Fiasp; Drug
Lead sponsor: Arecor Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Generalized Anxiety Disorder
Interventions: PF-06372865.; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 47
States / cities: Cerritos, California • Encino, California • Imperial, California + 41 more

Conditions: Obesity and Overweight
Interventions: MET097, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 3,578 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 37
States / cities: Scottsdale, Arizona • Canoga Park, California • Oxnard, California + 33 more

Conditions: Kidney Cancer
Interventions: PEG-interferon alfa-2b, Sorafenib, gene expression analysis, polymerase chain reaction, reverse transcriptase-polymerase chain reaction, flow cytometry, immunoenzyme technique, laboratory biomarker analysis; Biological · Drug · Genetic + 1 more
Lead sponsor: Thomas Olencki; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Magnetic Resonance Imaging, Alzheimer's Disease, Dementia, Adult Children, Risk
Interventions: Not listed
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 40 Years to 85 Years
Enrollment: 390 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2011
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Myopia
Interventions: Bausch + Lomb Samfilcon A Soft Contact Lens, Bausch + Lomb Pure Vision Soft Contact Lens; Device
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 816 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Cicero, New York

Conditions: Nasal Polyps
Interventions: Depemokimab (GSK3511294), Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 26
States / cities: Tucson, Arizona • Buena Park, California • Los Angeles, California + 22 more

Conditions: Postoperative Pain
Interventions: Ice; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Memory Impairment
Interventions: simultaneous aerobic exercise, sequential aerobic exercise, stretching and toning; Other
Lead sponsor: David Merrill, MD, PhD; Other
Eligibility: 60 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cystic Fibrosis
Interventions: inhaled hypertonic saline (7%); Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Ataxia-Telangiectasia (A-T)
Interventions: A-T iPS cell line, Carrier patients iPS cell line; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 3 Years to 100 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Prurigo Nodularis, Pruritis
Interventions: Vixarelimab, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 40
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 33 more

Conditions: Dry Eye Disease
Interventions: 0.003% AR-15512 ophthalmic solution, Artificial tears; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 6
States / cities: Newport Beach, California • Colorado Springs, Colorado • Andover, Massachusetts + 3 more

Conditions: Psoriasis
Interventions: Apremilast and Clobetasol; Combination Product
Lead sponsor: Washington Dermatology Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Hyperinsulinemic Hypoglycemia
Interventions: high carbohydrate test meal, high carbohydrate test meal after pre-treatment with rapid acting aspart insulin, high fructose , low glucose test meal with carbohydrate and caloric content similar to the control meal; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 21 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Healthy
Interventions: TA-65MD, Placebo; Dietary Supplement · Other
Lead sponsor: Telomerase Activation Sciences, Inc; Industry
Eligibility: 45 Years to 75 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Springfeild, Missouri

Conditions: Cleft Lip, Congenital Nose Malformation, Deformity, Nose Deformities, Acquired
Interventions: Cleft Lip/Nose Repair without PSIO, Presurgical Infant Orthopedic Therapy; Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 0 Months to 1 Month
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Colorectal Surgery
Interventions: Air insufflation with standard endoscopy unit, CO2 insufflation for colonoscopy (special CO2 insufflation unit); Procedure
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Alopecia, Radiodermatitis
Interventions: Norepinephrine; Drug
Lead sponsor: ProCertus BioPharm, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Major Depression, Bipolar Disorder, Unipolar Depression
Interventions: triiodothyronine, sertraline; Drug
Lead sponsor: Hadassah Medical Organization; Other
Eligibility: 18 Years to 70 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Mitral Regurgitation, Mitral Valve Disease, Mitral Annular Calcification
Interventions: Not listed
Lead sponsor: Universitätsklinikum Hamburg-Eppendorf; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 9
States / cities: Tucson, Arizona • Los Angeles, California • Tampa, Florida + 6 more

Search by objective public record fields.

Efficacy of Guselkumab in Treating Hailey Hailey Disease

Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer

End-stage Renal Disease (ESRD) Pilot Study

AT247, NovoLog® and Fiasp® Administered Via Continuous Subcutaneous Infusion in Glucose Clamp Study

POC Study in Partially Responsive Generalized Anxiety Disorder

Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity

PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer

fMRI of Vulnerable Brain Regions in Persons at Risk for Alzheimer's Disease

Silicone Hydrogel Soft Contact Lens 7-Day Extended Wear Basis

Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps

Ice Application for Postoperative Pain

Memory and Exercise Training Study in Older Adults With Subjective Memory Complaints

A Study of Lung Clearance After Hypertonic Saline Delivery Using the tPAD Device

Cell-Based Approaches For Modeling and Treating Ataxia-Telangiectasia

Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis

A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes

Apremilast in Combination With Clobetasol Spray for the Treatment of Plaque Psoriasis

Post-Gastric Bypass Hypoglycemia

Effect of TA-65MD on Healthy Volunteers

Fabrication of Sequential Naso-Alveolar Molding Appliances in the Treatment of Cleft Lip/Nose Deformities

Comparision of Air Versus CO2 for Distention During Sigmoidoscopy

Exploratory Study of Norepinephrine to Prevent Alopecia in Head and Neck Cancer Patients Treated With Radiotherapy

Triiodothyronine (T3) Supplementation in the Treatment of Bipolar and Unipolar Depression.

CHoice of OptImal transCatheter trEatment for Mitral Insufficiency Registry